High Thyroid Symptoms: Drugs That Cause or Treat Hyperthyroidism

What High Thyroid Symptoms Look and Feel Like

An overactive thyroid gland floods the bloodstream with excess thyroxine (T4) and triiodothyronine (T3), accelerating metabolism across virtually every organ system. The result is a constellation of symptoms that can mimic anxiety disorders, cardiac arrhythmias, or stimulant use.

The classic presentation includes unintentional weight loss despite increased appetite, resting heart rate above 100 bpm, fine tremor of the outstretched hands, heat intolerance with excessive sweating, and frequent loose bowel movements. Women may notice lighter or absent menstrual periods 1. Older adults often present atypically, sometimes showing only unexplained atrial fibrillation or apathy rather than the hyperkinetic picture seen in younger patients. The American Thyroid Association (ATA) notes that up to 15% of new atrial fibrillation cases are attributable to overt or subclinical hyperthyroidism 2.

Not all symptoms appear simultaneously. Some patients notice only palpitations and anxiety for months before weight loss begins. A suppressed TSH (below 0.1 mIU/L) with elevated free T4 confirms the diagnosis, but subclinical hyperthyroidism, where TSH is low while free T4 remains normal, can still produce symptoms and deserves monitoring 3.

Drugs That Can Cause Hyperthyroid Symptoms

Multiple prescription medications are known to induce thyroid overactivity. Recognizing the culprit drug is half the battle, because withdrawal of the offending agent may resolve symptoms without additional antithyroid treatment.

Amiodarone

Amiodarone is the single most common drug-induced cause of thyrotoxicosis. The molecule contains 37% iodine by weight, delivering roughly 7 mg of free iodine per 200 mg tablet, far exceeding the daily recommended intake of 150 mcg 4. Two distinct forms exist. Type 1 amiodarone-induced thyrotoxicosis (AIT-1) occurs in patients with underlying thyroid disease, where excess iodine drives new hormone synthesis. Type 2 (AIT-2) results from direct thyroid cell destruction and release of preformed hormone. A 2018 meta-analysis found that AIT develops in 3-5% of amiodarone-treated patients in iodine-sufficient regions and up to 15-20% in iodine-deficient areas 5.

Distinguishing the two types matters because AIT-1 responds to thionamides while AIT-2 responds to glucocorticoids. Mixed forms are common and often require both.

Immune Checkpoint Inhibitors

Drugs like nivolumab, pembrolizumab, and ipilimumab can trigger autoimmune thyroiditis. The thyroid gland is the most frequently affected endocrine organ during checkpoint inhibitor therapy. A 2019 systematic review reported thyroid dysfunction in 10-15% of patients receiving anti-PD-1 monotherapy, with overt thyrotoxicosis occurring in 3-8% 6. The typical pattern is a brief thyrotoxic phase (from gland destruction) followed by permanent hypothyroidism within 4-8 weeks. Dr. Megan Othus of the Fred Hutchinson Cancer Center has stated: "Checkpoint inhibitor thyroiditis is usually self-limiting in its hyperthyroid phase, but most patients will need lifelong levothyroxine afterward" 6.

Other Drug Culprits

Lithium rarely causes hyperthyroidism (it more commonly causes hypothyroidism), but case series document a 1-2% incidence of lithium-associated thyrotoxicosis, possibly through painless thyroiditis 7. Interferon-alfa, once widely used for hepatitis C, triggered autoimmune thyroid disease in 5-10% of patients 8. Tyrosine kinase inhibitors (sunitinib, sorafenib) can cause destructive thyroiditis. Iodinated contrast media used in CT scans can provoke iodine-induced hyperthyroidism (the Jod-Basedow phenomenon) in patients with autonomous thyroid nodules 9.

Excessive exogenous thyroid hormone (levothyroxine) is the most straightforward iatrogenic cause. Intentional TSH suppression for thyroid cancer patients and accidental over-replacement in hypothyroid patients both produce the full spectrum of hyperthyroid symptoms. A 2020 study found that 20% of levothyroxine users had a TSH below the reference range at least once over a 5-year follow-up 10.

First-Line Antithyroid Drugs: Methimazole and Propylthiouracil

Two thionamide drugs form the backbone of medical treatment for hyperthyroidism. Both block thyroid peroxidase, the enzyme responsible for incorporating iodine into thyroid hormone precursors.

Methimazole (MMI) is the preferred agent in nearly all clinical scenarios. The 2016 ATA guidelines recommend starting methimazole at 10-20 mg daily for moderate hyperthyroidism and up to 30-40 mg daily for severe disease 2. Its longer half-life (6-8 hours vs. 1-2 hours for PTU) allows once-daily dosing, improving adherence. A landmark trial by Abraham et al. showed that methimazole achieved euthyroidism in 94% of Graves disease patients within 6 weeks at a median dose of 15 mg daily 11.

Propylthiouracil (PTU) is reserved for two specific situations. It is the drug of choice during the first trimester of pregnancy because methimazole carries a small (2-4%) risk of embryopathy, including aplasia cutis and choanal atresia 12. PTU is also preferred in thyroid storm because it blocks peripheral conversion of T4 to the more active T3, an effect methimazole lacks.

Both drugs carry a risk of agranulocytosis (0.2-0.5%), a potentially fatal drop in white blood cells. The ATA recommends checking a baseline complete blood count and instructing patients to seek immediate medical attention for fever or sore throat during treatment 2. PTU also carries an FDA black-box warning for hepatotoxicity, which was added after reports of 32 cases of serious liver injury, including 12 requiring transplantation 13.

Typical duration of thionamide therapy for Graves disease is 12-18 months. Remission rates range from 40% to 60%, with higher odds in patients who are female, have mild disease, small goiters, and negative TRAb at the time of discontinuation 14.

Radioactive Iodine Therapy

Radioactive iodine (I-131) remains the most commonly used definitive treatment for Graves disease in the United States. The thyroid gland preferentially absorbs iodine, and I-131 emits beta radiation that destroys thyroid tissue over 6-18 weeks.

A single dose cures hyperthyroidism in 80-90% of patients 15. The trade-off is intentional. Most patients become hypothyroid and require lifelong levothyroxine replacement, which is considered a more stable and manageable condition than uncontrolled hyperthyroidism.

The 2016 ATA guidelines note: "RAI therapy is the most commonly chosen therapy by clinicians in the United States for uncomplicated Graves' hyperthyroidism" 2. Contraindications include pregnancy, breastfeeding, and coexisting moderate-to-severe Graves ophthalmopathy (radioactive iodine can worsen eye disease in 15-20% of cases unless covered with a short course of prednisone) 16.

Patients must follow radiation safety precautions for 2-5 days after treatment, including sleeping alone and limiting close contact with children and pregnant women. The administered dose is typically 10-15 mCi, adjusted based on thyroid gland size estimated by ultrasound or uptake scan.

Beta-Blockers for Symptom Control

Beta-blockers do not affect thyroid hormone levels. They control the adrenergic symptoms, specifically the palpitations, tremor, anxiety, and heat intolerance, that make hyperthyroidism miserable while definitive treatment takes effect.

Propranolol is the most frequently used beta-blocker for this indication because it also inhibits peripheral T4-to-T3 conversion at doses above 80 mg daily 17. Standard dosing is 20-40 mg every 6-8 hours, titrated to a resting heart rate below 90 bpm. Atenolol (25-100 mg daily) is a reasonable alternative for patients who need a once-daily regimen or have reactive airway concerns, though selective beta-1 blockers lose their selectivity at higher doses 2.

Beta-blockers should be started immediately at the time of diagnosis. They are safe in combination with thionamides or while awaiting radioactive iodine treatment. Taper rather than abruptly discontinue once thyroid levels normalize.

Thyroid Storm: Emergency Drug Management

Thyroid storm is a life-threatening exacerbation of hyperthyroidism with mortality rates between 8% and 25% despite aggressive treatment 18. It typically presents with fever above 104°F (40°C), altered mental status, tachycardia out of proportion to fever, and multiorgan dysfunction.

The treatment protocol layers multiple drugs simultaneously. PTU 500-1 to 000 mg loading dose (oral or via nasogastric tube) is preferred over methimazole because of its T4-to-T3 conversion blocking effect. One hour after PTU, saturated solution of potassium iodide (SSKI) 5 drops every 6 hours or Lugol solution 8 drops every 6 hours blocks further hormone release via the Wolff-Chaikoff effect 19. The one-hour delay is critical: giving iodine before PTU can paradoxically fuel new hormone synthesis.

Hydrocortisone 100 mg IV every 8 hours addresses potential adrenal insufficiency and further blocks T4-to-T3 conversion. Propranolol IV or oral (60-80 mg every 4 hours) controls the cardiovascular crisis. Cholestyramine 4 g four times daily can be added to bind thyroid hormone in the enterohepatic circulation, reducing serum T4 levels by an additional 30% in some series 20.

Newer and Adjunctive Drug Approaches

Cholestyramine, while primarily a bile acid sequestrant, has been used as adjunctive therapy in severe hyperthyroidism. A small randomized trial showed that adding cholestyramine 4 g four times daily to methimazole reduced free T4 levels 35% faster than methimazole alone over 4 weeks 20.

Selenium supplementation (200 mcg daily of sodium selenite) has shown benefit specifically for Graves ophthalmopathy. The EUGOGO trial (N=159) demonstrated that selenium reduced disease progression at 6 months compared to placebo (OR 0.36 to 95% CI 0.16-0.81), though it did not affect thyroid hormone levels directly 21.

Rituximab, an anti-CD20 monoclonal antibody, has been studied for refractory Graves disease in small case series. Results are mixed, and it is not part of standard guidelines. Teprotumumab (Tepezza), an IGF-1 receptor inhibitor FDA-approved for thyroid eye disease, does not treat hyperthyroidism itself but addresses one of its most debilitating complications 22.

When Drug-Induced Hyperthyroidism Requires a Different Approach

Managing drug-induced thyrotoxicosis depends on whether the offending medication can be safely stopped. Amiodarone presents a particular challenge because its half-life exceeds 100 days, meaning thyroid effects persist for months after discontinuation 4.

For AIT-1, methimazole 20-40 mg daily is the standard treatment. For AIT-2, prednisone 40-60 mg daily tapered over 2-3 months is preferred. Mixed or indeterminate forms often receive both methimazole and prednisone simultaneously 5. In life-threatening cases refractory to medical therapy, total thyroidectomy may be the fastest route to resolution, even in patients on anticoagulation or with significant cardiac comorbidities.

For checkpoint inhibitor thyroiditis, beta-blockers alone usually suffice during the hyperthyroid phase, which typically resolves within 3-6 weeks. Antithyroid drugs are generally unnecessary because the mechanism is hormone release from a damaged gland, not new hormone synthesis.

Iodine-contrast induced thyrotoxicosis in patients with known autonomous nodules can be prevented with prophylactic methimazole 20 mg daily for 2 weeks before and 2 weeks after contrast administration, combined with sodium perchlorate 500 mg twice daily 9.

Monitoring and Dose Adjustment During Treatment

After starting methimazole, thyroid function tests (TSH, free T4) should be checked every 4-6 weeks until euthyroidism is achieved 2. TSH may remain suppressed for several months even after free T4 normalizes due to pituitary TSH-producing cell recovery lag. Free T4 is therefore the better guide for early dose adjustments.

Once stable, monitoring intervals extend to every 3 months during the treatment course, then every 3 months for the first year after discontinuation to watch for relapse. The GREAT (Graves Recurrence Events After Therapy) score uses four variables (age, fT4 at diagnosis, TRAb titer, and goiter size by ultrasound) to estimate individual recurrence risk and can guide discussions about proceeding to definitive therapy 14.

Patients receiving radioactive iodine need TSH and free T4 checked at 4-6 weeks, 3 months, and then every 6-12 months for life. Levothyroxine replacement typically begins when TSH rises above 10 mIU/L or when symptoms of hypothyroidism emerge, whichever comes first.